Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis [0.03%]
Peginterferon β-1a可改善多发性硬化症患者的复发恢复状况
Thomas F Scott,Bernd C Kieseier,Scott D Newsome et al.
Thomas F Scott et al.
Background: Subcutaneous peginterferon beta-1a every 2 weeks significantly affects clinical outcomes in patients with relapsing-remitting multiple sclerosis (RRMS). ...
Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India [0.03%]
印度抗髓鞘少突胶质细胞糖蛋白抗体患者的临床表型以视神经炎复发和单相横贯性脊髓炎为主
Lekha Pandit,Douglas Kazutoshi Sato,Sharik Mustafa et al.
Lekha Pandit et al.
Background: Clinical phenotypes of patients with antibodies to myelin oligodendrocyte glycoprotein (anti-MOG+) are unknown in India. Objectives: ...
Analysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory [0.03%]
经典和现代测试理论在复发缓解型多发性硬化症中分析Multiple Sclerosis Impact Scale-29 (MSIS-29)的心理测量属性
E D Bacci,K W Wyrwich,G A Phillips et al.
E D Bacci et al.
Background: Investigations using classical test theory support the psychometric properties of the original version of the Multiple Sclerosis Impact Scale (MSIS-29v1), a disease-specific measure of multiple sclerosis (MS) ...
Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis [0.03%]
小剂量纳曲酮的长期治疗维持多发性硬化患者的健康状态
Michael D Ludwig,Anthony P Turel,Ian S Zagon et al.
Michael D Ludwig et al.
Introduction: A retrospective study was conducted on patients at Penn State Hershey Medical Center diagnosed with relapsing-remitting multiple sclerosis between 2006 and 2015. ...
Experience with long-term rituximab use in a multiple sclerosis clinic [0.03%]
利妥昔单抗在多发性硬化症患者中的长期应用经验
Megan E Barra,Dhruv Soni,Khac Huy Vo et al.
Megan E Barra et al.
Background: Rituximab is a monoclonal antibody directed at CD20 positive B-lymphocytes and a potential therapeutic option in the treatment of multiple sclerosis. The safety of recurrent dosing is not established. ...
Prevalence of multiple sclerosis in Latin America and its relationship with European migration [0.03%]
拉丁美洲多发性硬化的流行率及其与欧洲移民的关系
Edgar Correa,Víctor Paredes,Braulio Martínez
Edgar Correa
Multiple sclerosis (MS) is a chronic, degenerative autoimmune inflammatory disease of the central nervous system. The prevalence is different in every continent, changing according to geographical and environmental characteristics. The area...
Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis [0.03%]
复发缓解型多发性硬化症长期预后的预测因素
Anthony L Traboulsee,Peter Cornelisseª,Magnhild Sandberg-Wollheim et al.
Anthony L Traboulsee et al.
Objective: The objective of this article is to investigate potential clinical and MRI predictors of long-term outcomes in multiple sclerosis (MS). Methods...
Multiple sclerosis in First Nations Canadians: A pilot comparison study [0.03%]
加拿大第一民族人的多发性硬化症：一项初步比较研究
Ruth Ann Marrie,Nicholas Hall,A Dessa Sadovnick
Ruth Ann Marrie
Background: Genetic and clinical characteristics associated with multiple sclerosis (MS) may differ by ethnicity but few studies have evaluated whether characteristics of MS differ between individuals according to First N...
Risk attitudes and risk perceptions in individuals with multiple sclerosis [0.03%]
多发性硬化患者的个人风险态度及感知研究
Bonnie I Glanz,Emily Greeke,Allison LaRussa et al.
Bonnie I Glanz et al.
Background: Little is known about risk attitudes and risk perceptions in multiple sclerosis (MS). Objectives: The objectives of this pa...
Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis [0.03%]
自身造血干细胞移植治疗多发性硬化后发生的慢性炎症脱髓鞘多神经根神经病
Cecilia Smith Simonsen,Gunnar Hansen,Fredrik Piehl et al.
Cecilia Smith Simonsen et al.
We describe the case of a man in his 40 s with aggressive multiple sclerosis (MS) who received autologous haematopoietic stem cell transplantation (AHSCT) and subsequently developed probable, if not definite, Chronic Inflammatory Demyelinat...